|
IGF2BP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
8.39199999491669E-08 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.984870E-03 |
| Stage1-vs-Stage3 |
1.674370E-01 |
| Stage1-vs-Stage4 |
1.891850E-02 |
| Stage2-vs-Stage3 |
4.226000E-02 |
| Stage2-vs-Stage4 |
6.19130000000245E-05 |
| Stage3-vs-Stage4 |
9.416200E-04 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.16809919911998E-11 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
5.746400E-02 |
| Caucasian-vs-Asian |
1.402390E-01 |
| AfricanAmerican-vs-Asian |
2.845400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
4.317600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
7.017400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.369600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.488170E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.964200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.626200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.450400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.302400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.566000E-01 |
| Classical-VS-Follicular |
6.25632878836768E-12 |
| Classical-VS-Other |
4.644600E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
5.30910000406948E-08 |
| Tall-VS-Other |
4.488800E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
1.454580E-01 |
| Follicular-VS-Normal |
7.43594075203191E-12 |
| Other-VS-Normal |
1.919380E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.424200E-04 |
|
|
